Krystal Biotech Shares More Than Double During Premarket Monday: What Investors Need To KnowBenzinga • 11/29/21
Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis BullosaGlobeNewsWire • 11/29/21
Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational ProgressGlobeNewsWire • 11/08/21
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis BullosaGlobeNewsWire • 10/26/21
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic FibrosisGlobeNewsWire • 10/19/21
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCTGlobeNewsWire • 10/14/21
Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)GlobeNewsWire • 10/12/21
Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines ConferenceGlobeNewsWire • 10/01/21
Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic FibrosisGlobeNewsWire • 09/29/21
Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021GlobeNewsWire • 09/09/21
Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/07/21
Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational ProgressGlobeNewsWire • 08/09/21
Krystal Biotech's KB105 Shows Detectable, Functionally Active TGM-1 Enzyme In Genetic Skin ConditionBenzinga • 07/02/21
Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated IchthyosisGlobeNewsWire • 07/01/21
Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational ProgressGlobeNewsWire • 05/10/21
Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCTGlobeNewsWire • 04/27/21
Krystal Biotech Announces Completion of Patient Enrollment in the GEM-3 Pivotal Trial of B-VEC for the Treatment of Dystrophic Epidermolysis BullosaGlobeNewsWire • 03/30/21
Krystal Biotech Announces Launch of Jeune, a Gene-Based Aesthetics Company, and Initial Phase 1 Safety Data for KB301 in Aesthetic IndicationsGlobeNewsWire • 03/24/21
Krystal Biotech Provides Update on Operational Progress and Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 03/01/21